{"public_id":"cl_c70fd25ea4012d0e92c100775f151f62","status":"active","superseded_by_public_id":null,"corpus_id":10565127,"text":"Most symptomatic benefits appeared within 3 weeks, and symptom improvement was seen in nearly all patients with partial radiographic responses.","confidence":0.93,"paper":{"corpus_id":10565127,"title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.","url":"https://sah.borca.ai/papers/10565127"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_23506338cefffcec96e451bcdec57e91","name":"symptom improvement","description":"An increase in lung cancer symptom scores measured with the FACT-L lung cancer subscale.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_23506338cefffcec96e451bcdec57e91"},{"public_id":"co_2bda614e9af1a42f3e39ac916c02ccd1","name":"radiographic tumor regression","description":"A decrease in lesion size on imaging studies indicating tumor shrinkage.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_2bda614e9af1a42f3e39ac916c02ccd1"},{"public_id":"co_c8010c00975759f5055af9f2b9447799","name":"3 weeks","description":"The time window within which most symptom benefits were observed.","types":["time interval"],"url":"https://sah.borca.ai/concepts/co_c8010c00975759f5055af9f2b9447799"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c70fd25ea4012d0e92c100775f151f62"}